Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
- Analyses Estimate Humans Concentrate Lorcaserin in the Brain to a Much Lower Extent than Rats -<br>- Data to be Included in Response to Lorcaserin CRL -
View HTML
Toggle Summary Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
- Report to be Included in Response to Lorcaserin CRL -
View HTML
Toggle Summary Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California.
View HTML
Toggle Summary Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
-- Meeting Provides Additional Clarity on Next Steps Toward Approval --<br>-- Arena to Host Conference Call and Webcast at 8:30 a.m. Eastern Time Today --
View HTML
Toggle Summary Arena and Eisai Expand Marketing and Supply Agreement for Lorcaserin
New territories include Canada, Mexico and Brazil
View HTML
Toggle Summary Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
SAN DIEGO, and WOODCLIFF LAKE, N.J., Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available
View HTML
Toggle Summary Arena Announces That Merck & Co., Inc. Selects Arena-Discovered Compound for Advancement in Pre-Clinical Development
Merck-Arena Program Progresses From Research to Pre-Clinical Development in Two Years
View HTML
Toggle Summary Arena Pharmaceutcals raises IPO to 6 mln shares
Arena Pharmaceutcals raises IPO to 6 mln shares WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares. The company, which says it has developed technology that identifies drug
View HTML
Toggle Summary Arena Pharmaceuticals and Axiom Biotechnologies Sign Binding Letter of Intent for Research Collaboration and Equity Investment by Arena in Axiom
Arena Pharmaceuticals and Axiom Biotechnologies Sign Binding Letter of Intent for Research Collaboration and Equity Investment by Arena in Axiom SAN DIEGO--(BW HealthWire)--April 25, 2001-- The Collaborative Research Program Will Begin Immediately, and Arena's Purchase of $2 Million of Axiom
View HTML
Toggle Summary Arena Pharmaceuticals and CY Biotech Enter into Marketing and Supply Agreement for BELVIQ® (lorcaserin HCl) in Taiwan
SAN DIEGO , July 25, 2013 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH , has entered into an exclusive marketing and supply agreement with CY Biotech Company Ltd.
View HTML